CorAssist Cardiovascular - Innovative Solutions for heart failure with preserved ejection fraction (HFpEF)
Recognizing the unmet need in HFpEF therapy,
CorAssist introduces the CORolla device.
CorAssist Cardiovascular - Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

Current Treatment for Heart Failure with Preserved Ejection Fraction (HFpEF)

The treatment of patients with HFpEF (also known as Diastolic Heart Failure) is mainly empirical.
The treatment includes modification of the underlying risk factors for the disease (such as hypertension and diabetes) and administration of medications used for treating Heart Failure with reduced Ejection Fraction (also known as Systolic Heart Failure).

Presently, there are no medications or devices that proved to improve left ventricular relaxation and diastolic function.